前端編輯

管理員身份可於登入後,進行網站的前端管理。

 

5 1206011520542016.08 更新

圖片16

 5 1206011520542016.08 更新                                                                                                                                                    

抗體人類化與最佳化團隊

透過利用生物標記探討疾病偵測及追蹤之重要指標,進而評估疾病分期以及預測或觀察藥物之臨床反應,達到個人化醫療的目的。因此發展一個可用於早期診斷、術後追蹤與治療的策略是相當重要的。我們更透過特定的腫瘤生物標記開發用於診斷與治療抗體,將有助於新型抗藥物的發展。

 

平台名稱:
治療與診斷性抗體開發平台

 

基因診斷與基因藥物開發團隊

 

計畫名稱:
高血糖藉調控微小核糖核酸與相關標的基因對於第一期至第三期大腸直腸癌術後早期復發與存活之影響

 

平台名稱:
基因診斷與基因藥物開發平台

 

大腸癌治療研發團隊

大腸癌治療研發團隊,獲得校內外多項計畫補助

 

計畫名稱:
1. 大腸直腸癌早期診斷、預測預後評估之生物標誌的探討
2. 大腸直腸癌早期偵測與標靶佐劑療法之建立
3. 訊息核醣核酸與微小核醣核酸之驗證與臨床應用:早期偵測大腸直腸癌術後早期復發
4. 高血糖藉調控微小核糖核酸與相關標的基因對於第一期至第三期大腸直腸癌術後早期復發與存活之影響
5. 研發並驗證能預測局部進行期直腸癌病患接受手術前同步化學放射療法療效之腫瘤組織的微小核糖核酸與傳訊核糖核酸
6. 結直腸癌病人預防、診斷和治療之經濟評估
7. 大腸直腸癌藥理基因體學研究與個人化醫療之臨床應用
8. 粒腺體中轉譯後修飾蛋白質作為大腸癌早期診斷的生物標誌
9. 細胞外膜泡在大腸直腸癌血管新生之探討,並建立抗VEGF 治療法之生物標記
10. 以具蛋白酶活化特性之前驅抗體進行大腸癌專一性治療並降低副作用

 

全人類化抗體藥物團隊

現今抗體藥物已逐漸成為臨床的主流用藥。根據2010年統計,抗體藥物年總銷售額達四百億美金之多,且市場仍持續快速的成長。然而目前發展全人類抗體藥物的方法面臨到效率低、準確率低、細胞抗體分泌能力低下及免疫抗性等問題。因此發展精確且高效率的全人類抗體開發策略是很重要的。 

 

計畫名稱:
利用腫瘤浸潤B細胞開發新穎大腸直腸癌診斷及治療標的之專一性抗體藥物

 

由鄭添祿 主任主持的開發團隊,獲得校內多項計畫補助,通過多項專利申請 圖片5 5 1206011520542016.08 更新圖片65 1206011520542016.08 更新

圖片7

5 1206011520542016.08 更新

圖片85 1206011520542016.08 更新

圖片9

5 1206011520542016.08 更新

Publications:

2008~2016 Publications5 1206011520542016.08 更新

2016 Publications

  1. Prijovich ZM, Burnouf PA, Chou HC, Huang PT, Chen KC,Cheng TL, Leu YL, Roffler SR.Synthesis and Antitumor Properties of BQC-Glucuronide, a Camptothecin Prodrug for Selective Tumor Activation.Mol Pharm. 2016 Apr 4;13(4):1242-50.
  2. Huang WC, Burnouf PA, Su YC, Chen BM, Chuang KH, Lee CW, Wei PK,Cheng TL*, Roffler SR*.Engineering Chimeric Receptors To Investigate the Size- and Rigidity-Dependent Interaction of PEGylated Nanoparticles with Cells.ACS Nano. 2016 Jan 26;10(1):648-62.

2015Publications

  1. Huang CC, Kuo KK, Cheng TC, Chuang CH, Kao CH, Hsieh YC, Cheng KH, Wang JY, Cheng CM, Chen CS,Cheng TL*.Development of Membrane-Bound GM-CSF and IL-18 as an Effective Tumor Vaccine.PLoS One. 2015 Jul 17;10(7):
  2. Cheng TC, Pan CH, Chen CS, Chuang KH, Chuang CH, Huang CC, Chu YY, Yang YC, Chu PY, Kao CH, Hsieh YC,Cheng TL*.Direct coating of culture medium from cells secreting classical swine fever virus E2 antigen on ELISA plates for detection of E2-specific antibodies.Vet J. 2015 Jul;205(1):107-9.
  3. Tung HY, Su YC, Chen BM, Burnouf PA, Huang WC, Chuang KH, Yan YT,Cheng TL, Roffler SR.Selective Delivery of PEGylated Compounds to Tumor Cells by Anti-PEG Hybrid Antibodies.Mol Cancer Ther. 2015 Jun;14(6):1317-26.
  4. Cheng TC, Chuang KH, Roffler SR, Cheng KW, Leu YL, Chuang CH, Huang CC, Kao CH, Hsieh YC, Chang LS,Cheng TL*, Chen CS*. Discovery of specific inhibitors for intestinal E. coli  β-glucuronidase through in silico virtual screening.
  5. Hsieh YT, Chen KC, Cheng CM, Cheng TL, Tao MH, Roffler SR. Impediments to Enhancement of CPT-11 Anticancer Activity by E. coli Directed Beta-Glucuronidase Therapy.PLoS One. 2015 Feb 17;10(2):e0118028.
  6. Changchien JJ, Chen YJ, Huang CH, Cheng TL, Lin SR, Chang LS. Quinacrine induces apoptosis in human leukemia K562 cells via p38 MAPK-elicited BCL2 down-regulation and suppression of ERK/c-Jun-mediated BCL2L1 expression.Toxicol Appl Pharmacol. 2015 Apr 1;284(1):33-41

2014 Publications

  1. Su YC, Cheng TC, Leu YL, Roffler SR, Wang JY, Chuang CH, Kao CH, Chen KC, Wang HE, Cheng TL*.PET Imaging of β-Glucuronidase Activity by an Activity-Based 124I-Trapping Probe for the Personalized Glucuronide Prodrug Targeted Therapy.Mol Cancer Ther. 2014 Dec;13(12):2852-63. 2013 IF=6.107 (23/202=11.38 in ONCOLOGY.
  2. Chien-Han Kao, Jaw-Yuan Wang, Kuo-Hsiang Chuang, Chih-Hung Chuang, Ta-Chun Cheng, Yuan-Chin Hsieh, Yun-long Tseng, Bing-Mae Chen, Steve R. Roffler, Tian-Lu Cheng*. One-step mixing with humanized anti-mPEG bispecific antibody enhances tumor accumulation and therapeutic efficacy of mPEGylated nanoparticles.Biomaterials. 2014 Dec;35(37):9930-40. 2013 IF=8.312 (2/77=2.5%) in ENGINEERING, BIOMEDICAL.
  3. Kuo-Hsiang Chuang,Chien-Han Kao,Steve R. Roffler,Ssu-Jung Lu,Ta-Chun Cheng, Yun-Ming Wang,Chih-Hung Chuang,Yuan-Chin Hsieh,Yeng-Tseng Wang,Jaw-Yuan Wang,Kuo-Yi Wengand Tian-Lu Cheng*. Development of an Anti-Methoxy Poly(ethylene glycol) (α-mPEG) Cell-Based Capture System to Measure mPEG and mPEGylated Molecules. Macromolecules.2014, 47, 6880−6888.2013 IF=5.927 (3/82, 3.7%) in POLYMER SCIENCE.
  4. Kuo-Hsiang Chuang, Yuan-Chin Hsieh, I-Shiuan Chiang, Chih-Hung Chuang, Chien-Han Kao, Ta-Chun Cheng, Yeng-Tseng Wang, Wen-Wei Lin, Bing-Mae Chen, Steve R. Roffler, Ming-Yii Huang, Tian-Lu Cheng*. High-Throughput Sorting of the Highest Producing Cell via a Transiently Protein-Anchored System.PLoS One. 2014 Jul 18;9(7):e102569. 2013 (8/55=14.5% in MULTIDISCIPLINARY SCIENCES
  5. Cheng CM, Tzou SC, Zhuang YH, Huang CC, Kao CH, Liao KW, Cheng TC, Chuang CH, Hsieh YC, Tai MH, Cheng TL*. FunctionalproductionPLoS One. 2014 May 13;9(5):e97367.2013 (8/55=14.5% in MULTIDISCIPLINARY SCIENCES
  6. Chen YJ, Lin HC, Chen KC, Lin SR, Cheng TL, Chang LS. Taiwan cobra phospholipase A2 suppresses ERK-mediated ADAM17 maturation, thus reducing secreted TNF-α production in human leukemia U937 cells.Toxicon. 2014 May 27;86C:79-88.
  7. Su YC, Al-Qaisi TS, Tung HY, Cheng TL, Chuang KH, Chen BM, Roffler SR. Mimicking the germinal center reaction in hybridoma cells to isolate temperature-selective anti-PEG antibodies.MAbs. 2014 May 14;6(4).
  8. Chuang CH, Wang WJ, Li CF, Ko CY, Chou YH, Chuu CP, Cheng TL*, Wang JM*. The combination of the prodrugs perforin-CEBPD and perforin-granzyme B efficiently enhances the activation of caspase signaling and kills prostate cancer.Cell Death Dis. 2014 May 8;5:e1220.2013 IF=5.177 (49/185=26.5%) in CELL BIOLOGY.
  9. Chen YJ, Wu SC, Chen CY, Tzou SC, Cheng TL, Huang YF, Yuan SS, Wang YM. Peptide-based MRI contrast agent and near-infrared fluorescent probe for intratumoral legumain detection.

2013 publications

  1. Cheng TC, Chuang KH, Chen M, Wang HE, Tzou SC, Su YC, Chuang CH, Kao CH, Chen BM, Chang LS, Roffler SR, Cheng TL*.Sensitivity of PEGylated interferon detection by anti-polyethylene glycol (PEG) antibodies depends on PEG length.Bioconjug Chem.2013 Aug 21;24(8):1408-13.2013 IF=4.821 (7/58=12.1%) in CHEMISTRY, ORGANIC
  2. Liu WH, Chen YJ, Cheng TL, Lin SR, Chang LS.Cross talk between p38MAPK and ERK is mediated through MAPK-mediated protein phosphatase 2A catalytic subunit α and MAPK phosphatase-1 expression in human leukemia U937 cells.Cell Signal. 2013 Sep;25(9):1845-51
  3. Chen SH, Kuo YT, Cheng TL, Chen CY, Chiu YY, Lai JJ, Chang CC, Jaw TS, Wang YM, Liu GC.In vivo magnetic resonance imaging of mice liver tumors using a new gadolinium-based contrast agent.  Kaohsiung J Med Sci. 2013 May;29(5):246-53.
  4. Cheng CM, Chen FM, Lu YL, Tzou SC, Wang JY, Kao CH, Liao KW, Cheng TC, Chuang CH, Chen BM, Roffler S,Cheng TL*.Expression of β-glucuronidase on the surface of bacteria enhances activation of glucuronide prodrugs.Cancer Gene Ther. 2013 May;20(5):276-81. 2013 IF=2.553 (58/165=35.2%) in BIOTECHNOLOGY & APPLIED MICROBIOLOGY.
  5. Wu SC, Lin KL, Wang TP, Tzou SC, Singh G, Chen MH, Cheng TL, Chen CY, Liu GC, Lee TW, Hu SH, Wang YM.Imaging specificity of MR-optical imaging agents following the masking of surface charge by poly(ethylene glycol). 2013 May;34(16):4118-27.
  6. Lu CY, Tsai HL, Uen YH, Hu HM, Chen CW, Cheng TL, Lin SR, Wang JY. Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer.Br J Cancer. 2013 Mar 5;108(4):791-7.
Go to top